Regeneron Pharmaceuticals, Inc. $REGN Stock: Allianz SE Grows Holdings

Allianz SE raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 13,732.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,288 shares of the biopharmaceutical company’s stock after purchasing an additional 4,257 shares during the period. Allianz SE’s holdings in Regeneron Pharmaceuticals were worth $3,251,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Sumitomo Mitsui Financial Group Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $152,000. State Street Corp grew its stake in shares of Regeneron Pharmaceuticals by 1.0% during the third quarter. State Street Corp now owns 4,881,362 shares of the biopharmaceutical company’s stock worth $3,701,390,000 after purchasing an additional 46,674 shares during the period. Fort Sheridan Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter valued at about $212,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in Regeneron Pharmaceuticals by 44.1% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 895 shares of the biopharmaceutical company’s stock valued at $679,000 after purchasing an additional 274 shares during the last quarter. Finally, TIAA CREF Individual & Institutional Services LLC increased its holdings in Regeneron Pharmaceuticals by 5.6% in the third quarter. TIAA CREF Individual & Institutional Services LLC now owns 1,635 shares of the biopharmaceutical company’s stock valued at $1,240,000 after purchasing an additional 87 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Truist Financial increased their target price on Regeneron Pharmaceuticals from $780.00 to $982.00 and gave the company a “buy” rating in a research note on Monday, November 2nd. Zacks Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. Wall Street Zen raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 20th. Canaccord Genuity Group upped their price target on Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Finally, BMO Capital Markets increased their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $904.41.

Read Our Latest Stock Analysis on Regeneron Pharmaceuticals

Insider Activity

In other news, Director Huda Y. Zoghbi sold 7,439 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $970.46, for a total value of $7,219,251.94. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,652,693.38. The trade was a 81.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Andrew J. Murphy sold 5,011 shares of the business’s stock in a transaction dated Tuesday, November 17th. The shares were sold at an average price of $957.76, for a total value of $4,799,335.36. Following the completion of the sale, the insider owned 46,779 shares in the company, valued at approximately $44,803,055.04. This trade represents a 9.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 32,039 shares of company stock worth $29,825,285. 6.97% of the stock is currently owned by insiders.

Key Headlines Impacting Regeneron Pharmaceuticals

Investors following REGN have been watching these headlines:

  • Positive Sentiment: The FDA approved Livsayis (cemdisiran) for adults with anti-AChR-positive generalized myasthenia gravis. It is the first approved siRNA therapy for the condition and the only treatment given by subcutaneous injection just four times a year. Phase 3 results showed sustained disease control between doses, giving Regeneron a new neurology product and potential revenue source. Livsayis FDA approval announcement
  • Positive Sentiment: The European Commission approved more flexible Libtayo dosing across six cancer indications. The change could improve convenience for patients and support Regeneron’s oncology business. Libtayo dosing flexibility approval
  • Neutral Sentiment: Livsayis will compete with established treatments for generalized myasthenia gravis, so adoption and commercial performance remain important to watch despite its distinctive dosing schedule. Livsayis competitive context

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $920.69 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.35. Regeneron Pharmaceuticals, Inc. has a 52 week low of $591.52 and a 52 week high of $991.73. The company’s 50 day moving average price is $829.76 and its two-hundred day moving average price is $752.07. The company has a market capitalization of $95.25 billion, a P/E ratio of 20.33, a price-to-earnings-growth ratio of 1.22 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. During the same quarter in the prior year, the company earned $11.83 earnings per share. The business’s quarterly revenue was up 36.3% compared to the same quarter last year. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be paid a $0.94 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.30%.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Read More

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.